Cancer Chemotherapy and Pharmacology

Cancer Chemotherapy and Pharmacology is a specialist journal in oncology pharmacology published by Springer in Germany. Founded in 1978, it reports preclinical and clinical pharmacology of anticancer drugs with an emphasis on pharmacokinetics and pharmacodynamics, and is now published online only.Cancer Chemotherapy and Pharmacology（癌症化疗与药理学）是Springer（德国）出版的肿瘤药理学专业期刊，创刊于 1978 年，刊载抗肿瘤药物的临床前与临床药理学研究，重点覆盖药代动力学与药效动力学，现为纯在线出版。^[1]

Scope

• The journal reports preclinical and clinical pharmacology of anticancer drugs, covering pharmacokinetic and pharmacodynamic aspects.期刊报告抗肿瘤药物的临床前与临床药理学研究，涵盖药代动力学与药效动力学两个方面。^[2]
• The areas explicitly covered are pharmacokinetics, pharmacodynamics, drug interactions, exposure-response relationships, and predictors of response or toxicity.明确列出的收录领域为药代动力学、药效动力学、药物相互作用、暴露量与反应关系，以及疗效或毒性的预测因子。*
• At the experimental level, it addresses the screening of new anticancer agents, preclinical toxicology and pharmacology, and studies of single-agent and combination modalities.在实验层面，期刊关注新型抗肿瘤药物的实验筛选、临床前毒理学与药理学，以及单药与联合给药模式的研究。*
• At the clinical level, it reports results from phase I, II and III trials, serving both pharmacologists and oncologists.在临床层面，期刊收录一期、二期与三期临床试验的结果，服务于药物学家与肿瘤学家两类读者。*
• As a rapid-publication outlet it has a very short median time from submission to first decision, and its author instructions require suggested reviewers to be supplied at submission.作为快速出版平台，投稿至首次决定的周期很短，投稿说明亦要求作者在投稿时同步提交外部审稿人的推荐名单。*

该刊的定位高度专门化，与综合性肿瘤学期刊存在明确分工：它关注药物在体内的吸收、分布、代谢与排泄过程，以及给药方案与毒性、疗效之间的定量关系，而非疾病预后或临床结局本身。这一取向使其在药理学口径下稳定地被引用，即使其整体影响因子相对温和。对肿瘤药理研究者而言，该刊是把临床用药方案追溯到药物代谢与剂量个体化证据的主要文献来源。

History

• 1978: Founded and published by Springer in Germany, the journal has centred on the pharmacology of anticancer drugs since its first issue.1978：创刊，由 Springer 在德国出版，自创刊起即以抗肿瘤药物的药理学研究为核心主题。*
• 1978 to the 2010s: The editor-in-chief changed several times, with Edward A. Sausville serving in the post and Etienne Chatelut remaining on the board for many years and continuing to the present.1978 至 2010 年代：主编人选多次更替，Edward A. Sausville 曾担任主编，Étienne Chatelut 亦长期在编并延续至今。*
• Recent years: Jan Hendrik Beumer joined the editorial leadership, and he and Etienne Chatelut now serve as Editors-in-Chief together.近年：Jan Hendrik Beumer 加入主编行列，现由他与 Étienne Chatelut 共同担任主编。*
• Recent years: The journal moved from print to online-only publication, its former print ISSN 0344-5704 has been discontinued, and only the electronic ISSN 1432-0843 is now in use.近年：已由印刷版转为纯在线出版，原印刷版国际标准刊号 0344-5704 停止使用，现仅保留电子版国际标准刊号 1432-0843。*
• Recent years: The publishing model is hybrid with an open access option retained, and two standing collections have been established to support the scholarly community and emerging researchers.近年：出版模式为混合制，保留开放获取选项，同时设有两个常设专栏以推动学术共同体建设与新人扶持。*

Editors

本刊实行双主编制，由两位在肿瘤药理学与转化肿瘤学领域各有专长的学者共同担任主编。这种安排便于同时覆盖临床药理学与实验药理学两条线索，也契合该刊横跨临床前研究与临床试验的收录范围。

• Editors-in-Chief: Jan Hendrik Beumer and Etienne Chatelut serve as Editors-in-Chief, the former at Johns Hopkins University in the United States and the latter at the Institut universitaire du cancer de Toulouse Oncopole in France.主编：Jan Hendrik Beumer 与 Étienne Chatelut 共同担任本刊主编；前者任职于约翰斯·霍普金斯大学（美国），后者任职于图卢兹大学肿瘤研究所（法国）。*
• Board composition: The board draws on cancer centres and research institutions in several countries, including Vassilios G. Aslanis, Frank Balis, Alan Boddy, Michael Carducci, Joseph Ciccolini, Ashkan Emadi, Nielka P. van Erp, William Douglas Figg, Yasuhiro Fujiwara, Elisa Giovannetti, Georg Hempel, Peter Houghton, Lars Peter Jordheim and Godefridus J. Peters.编委构成：编委成员来自多个国家的肿瘤中心与研究机构，包括 Vassilios G. Aslanis、Frank Balis、Alan Boddy、Michael Carducci、Joseph Ciccolini、Ashkan Emadi、Nielka P. van Erp、William Douglas Figg、Yasuhiro Fujiwara、Elisa Giovannetti、Georg Hempel、Peter Houghton、Lars Peter Jordheim 与 Godefridus J. Peters 等。*
• Institutional spread: Their affiliations include the Children's Hospital of Philadelphia, the University of South Australia, the Johns Hopkins Kimmel Cancer Center, Aix-Marseille University, West Virginia University, Radboud University, the United States National Institutes of Health, the Japanese Pharmaceuticals and Medical Devices Agency, Amsterdam University Medical Centers, the University of Munster, the University of Texas Health Science Center at San Antonio and the Lyon Cancer Research Centre.机构分布：编委成员的所属机构包括费城儿童医院、南澳大利亚大学、霍普金斯金梅尔癌症中心、马赛大学、西弗吉尼亚大学、莱顿伊拉斯谟学院、美国国立卫生研究院、日本药品医疗器械综合机构、阿姆斯特丹大学医学中心、明斯特大学、得克萨斯大学圣安东尼奥分校与里昂癌症研究中心等。*
• Standing collections: The journal runs an invited review series highlighting recent advances and emerging strategies in cancer chemotherapy and pharmacology, alongside a second collection for emerging researchers in oncology.常设专栏：期刊设'''Cancer Chemotherapy and Pharmacology'' 系列综述专栏，持续邀约并突出肿瘤化疗领域的近期进展与新兴策略，另设面向肿瘤学新人的专栏。*